Genetic Analysis of a Cohort of 275 Patients With Hyper-Ige Syndromes And/Or Chronic Mucocutaneous Candidiasis Publisher Pubmed



Frede N^{1, 2} ; Rojasrestrepo J^{1, 3} ; Caballero Garcia De Oteyza A^{1, 3} ; Buchta M¹ ; Hubscher K^{1, 3} ; Gamezdiaz L^{1, 3} ; Proietti M^{1, 3} ; Saghafi S⁴ ; Chavoshzadeh Z⁵ ; Solerpalacin P⁶ ; Galal N⁷ ; Adeli M⁸ ; Aldavebecerra JC⁹ ; Alddafari MS¹⁰ Show All Authors Show Affiliations
Source: Journal of Clinical Immunology Published:2021

Abstract

Hyper-IgE syndromes and chronic mucocutaneous candidiasis constitute rare primary immunodeficiency syndromes with an overlapping clinical phenotype. In recent years, a growing number of underlying genetic defects have been identified. To characterize the underlying genetic defects in a large international cohort of 275 patients, of whom 211 had been clinically diagnosed with hyper-IgE syndrome and 64 with chronic mucocutaneous candidiasis, targeted panel sequencing was performed, relying on Agilent HaloPlex and Illumina MiSeq technologies. The targeted panel sequencing approach allowed us to identify 87 (32 novel and 55 previously described) mutations in 78 patients, which generated a diagnostic success rate of 28.4%. Specifically, mutations in DOCK8 (26 patients), STAT3 (21), STAT1 (15), CARD9 (6), AIRE (3), IL17RA (2), SPINK5 (3), ZNF341 (2), CARMIL2/RLTPR (1), IL12RB1 (1), and WAS (1) have been detected. The most common clinical findings in this cohort were elevated IgE (81.5%), eczema (71.7%), and eosinophilia (62.9%). Regarding infections, 54.7% of patients had a history of radiologically proven pneumonia, and 28.3% have had other serious infections. History of fungal infection was noted in 53% of cases and skin abscesses in 52.9%. Skeletal or dental abnormalities were observed in 46.2% of patients with a characteristic face being the most commonly reported feature (23.1%), followed by retained primary teeth in 18.9% of patients. Targeted panel sequencing provides a cost-effective first-line genetic screening method which allows for the identification of mutations also in patients with atypical clinical presentations and should be routinely implemented in referral centers. © 2021, The Author(s).